JP4799666B2 - 結晶形態のｇｌｙｔ１ - Google Patents

結晶形態のｇｌｙｔ１ Download PDF

Info

Publication number
JP4799666B2
JP4799666B2 JP2009543441A JP2009543441A JP4799666B2 JP 4799666 B2 JP4799666 B2 JP 4799666B2 JP 2009543441 A JP2009543441 A JP 2009543441A JP 2009543441 A JP2009543441 A JP 2009543441A JP 4799666 B2 JP4799666 B2 JP 4799666B2
Authority
JP
Japan
Prior art keywords
methyl
fluoro
methanone
trifluoromethyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009543441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514725A5 (enExample
JP2010514725A (ja
Inventor
ブーベンドルフ，アンドレ
ディーネット−ヴツェノヴィッチ，アネット
ディオドーネ，ラルフ
グラスマン，オラフ
リンデンストルート，カイ
ピナール，エマニュエル
ローレル，フランツィスカ・エー
シュヴィッター，ウルス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4799666(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2010514725A publication Critical patent/JP2010514725A/ja
Publication of JP2010514725A5 publication Critical patent/JP2010514725A5/ja
Application granted granted Critical
Publication of JP4799666B2 publication Critical patent/JP4799666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2009543441A 2006-12-28 2007-12-18 結晶形態のｇｌｙｔ１ Active JP4799666B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269.6 2006-12-28
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (3)

Publication Number Publication Date
JP2010514725A JP2010514725A (ja) 2010-05-06
JP2010514725A5 JP2010514725A5 (enExample) 2010-12-02
JP4799666B2 true JP4799666B2 (ja) 2011-10-26

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543441A Active JP4799666B2 (ja) 2006-12-28 2007-12-18 結晶形態のｇｌｙｔ１

Country Status (33)

Country Link
US (5) US20080214561A1 (enExample)
EP (1) EP2114405B1 (enExample)
JP (1) JP4799666B2 (enExample)
KR (1) KR101130146B1 (enExample)
CN (1) CN101573114A (enExample)
AR (1) AR064545A1 (enExample)
AU (1) AU2007341356B2 (enExample)
BR (1) BRPI0720829B8 (enExample)
CA (1) CA2673667A1 (enExample)
CL (1) CL2007003830A1 (enExample)
CO (1) CO6190613A2 (enExample)
CR (1) CR10846A (enExample)
CY (1) CY1116350T1 (enExample)
DK (1) DK2114405T3 (enExample)
EC (1) ECSP099471A (enExample)
ES (1) ES2535040T3 (enExample)
HR (1) HRP20150573T1 (enExample)
HU (1) HUE025032T2 (enExample)
MA (1) MA31029B1 (enExample)
MX (1) MX2009006859A (enExample)
MY (1) MY188367A (enExample)
NO (1) NO342150B1 (enExample)
NZ (1) NZ577502A (enExample)
PE (1) PE20081556A1 (enExample)
PL (1) PL2114405T3 (enExample)
PT (1) PT2114405E (enExample)
RS (1) RS53910B1 (enExample)
RU (1) RU2463295C2 (enExample)
SI (1) SI2114405T1 (enExample)
TW (1) TWI388552B (enExample)
UA (1) UA100232C2 (enExample)
WO (1) WO2008080821A1 (enExample)
ZA (1) ZA200904423B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
EP2855462A1 (en) * 2012-05-25 2015-04-08 Basf Se Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1

Also Published As

Publication number Publication date
US20080214561A1 (en) 2008-09-04
PT2114405E (pt) 2015-06-02
BRPI0720829B8 (pt) 2021-05-25
AU2007341356A1 (en) 2008-07-10
US8039473B2 (en) 2011-10-18
CY1116350T1 (el) 2017-03-15
BRPI0720829A2 (pt) 2014-02-25
TW200833677A (en) 2008-08-16
AU2007341356B2 (en) 2013-08-29
UA100232C2 (uk) 2012-12-10
CN101573114A (zh) 2009-11-04
BRPI0720829B1 (pt) 2020-04-07
NZ577502A (en) 2012-02-24
KR101130146B1 (ko) 2012-03-28
CA2673667A1 (en) 2008-07-10
PL2114405T3 (pl) 2015-08-31
MX2009006859A (es) 2009-07-03
CO6190613A2 (es) 2010-08-19
SI2114405T1 (sl) 2015-06-30
CR10846A (es) 2009-08-12
RS53910B1 (sr) 2015-08-31
AR064545A1 (es) 2009-04-08
CL2007003830A1 (es) 2008-07-11
ZA200904423B (en) 2010-05-26
HUE025032T2 (en) 2016-02-29
HRP20150573T1 (xx) 2015-07-03
PE20081556A1 (es) 2008-11-28
US20130197225A1 (en) 2013-08-01
ECSP099471A (es) 2009-07-31
KR20090094166A (ko) 2009-09-03
EP2114405B1 (en) 2015-03-11
DK2114405T3 (en) 2015-04-07
RU2463295C2 (ru) 2012-10-10
US20110295007A1 (en) 2011-12-01
MA31029B1 (fr) 2009-12-01
ES2535040T3 (es) 2015-05-04
NO20092358L (no) 2009-06-22
TWI388552B (zh) 2013-03-11
US20120309969A1 (en) 2012-12-06
US20100311971A1 (en) 2010-12-09
JP2010514725A (ja) 2010-05-06
EP2114405A1 (en) 2009-11-11
WO2008080821A1 (en) 2008-07-10
NO342150B1 (no) 2018-04-03
MY188367A (en) 2021-12-06
RU2009124113A (ru) 2011-02-10

Similar Documents

Publication Publication Date Title
JP4799666B2 (ja) 結晶形態のｇｌｙｔ１
RU2460728C2 (ru) Соль моносульфат 2-хлор-4-[1-(4-фторфенил)-2,5-диметил-1н-имидазол-4-илэтинил]-пиридина и ее кристаллическая форма, содержащая их фармацевтическая композиция и способ получения
CN114026088A (zh) Jak2抑制剂的结晶形式
HK1136207A (en) Crystalline forms glyt1
TW202527943A (zh) 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式
BRPI0720954B1 (pt) Forma cristalina do sal de monossulfato de um antagonista de receptor mglur5, seu uso, processo de preparação do mesmo e composição farmacêutica que o compreende

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101018

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20101018

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20101109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110802

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140812

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4799666

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250